WO2025207067 - A TABLET COMPRISING TENOFOVIR ALAFENAMIDE MONOFUMARATE
National phase entry is expected:
Publication Number
WO/2025/207067
Publication Date
02.10.2025
International Application No.
PCT/TR2025/050297
International Filing Date
25.03.2025
Title **
[English]
A TABLET COMPRISING TENOFOVIR ALAFENAMIDE MONOFUMARATE
[French]
COMPRIMÉ COMPRENANT DU MONOFUMARATE DE TÉNOFOVIR ALAFÉNAMIDE
Applicants **
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
Inventors
SUNEL, Fatih
ATAK, Fadime Bilgehan
IPEK, Celaleddin
GENCAL, Aynur
ATAMAN, Seval
DERELI, Selin
KAPTAN, Ayca
Priority Data
2024/003829
28.03.2024
TR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
Turkpatent
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2099 | |
| EPO | Filing, Examination, Granting | 9189 | |
| Japan | Filing, Examination, Granting | 2170 | |
| South Korea | Filing, Examination, Granting | 2125 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
20,323
Contact Us
Abstract[English]
The present invention relates to a tablet composition comprising tenofovir alafenamide monofumarate and at least one pharmaceutically acceptable excipient, wherein tenofovir alafenamide monofumarate has a d (0.9) particle size between 85 µm and 20 µm. The present invention also relates to a simple, rapid, cost effective, time-saving and a solvent-free process of preparing the composition.[French]
La présente invention concerne une composition de comprimé comprenant du monofumarate de ténofovir alafénamide et au moins un excipient pharmaceutiquement acceptable, le monofumarate de ténofovir alafénamide ayant une taille de particule d (0,9) comprise entre 85 µm et 20 µm. La présente invention concerne également un procédé simple, rapide, économique, économe en temps et sans solvant de préparation de la composition.